Events

Date: Tuesday, November 7, 2023 Time: 2:00pm - 3:00pm ET TITLE: Case Studies of Using BeneFix® (Coagulation Factor IX ) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story? SPEAKER: Doris Quon, MD Medical Director of the Orthopaedic Hemophilia Treatment Center at the Luskin Orthopaedic Institute Read the full article...

Date: Thursday, November 9, 2023 Time: 1:00pm - 2:00pm ET TITLE: Learn More About Subcutaneous Prophylaxis Treatment for Hemophilia A: A Discussion on the Latest Data and Patient Management DESCRIPTION: Please join us for an engaging webinar led by Ketna Mistry, MD who will be sharing information on patients with hemophilia A with a subcutaneous Read the full article...

Date: Monday, November 13, 2023 Time: 1:00pm - 2:00pm ET TITLE: Hemgenix Real World Learnings SPEAKER: Vidhi Desai, MD Senior Medical Director, Coagulation North America Medical Affairs Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Idelvion®, Read the full article...

Date: Friday, November 17, 2023 Time: 1:00pm - 2:00pm ET TOPIC: Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® OVERVIEW: This session includes key information about Jivi including, safety and efficacy data from the clinical trials, step-wise dosing and Jivi RWE Data from HEM-POWR, Read the full article...

Date: Monday, November 27, 2023 Time: 1:00pm - 2:00pm ET TITLE: A different treatment option for Inhibitor patients OBJECTIVE: This presentation will provide an overview of inhibitors and explore the efficacy, safety, tolerability, clinical development, and reasons to consider a different treatment option. TARGET AUDIENCE: All HTC Staff SPEAKER: Guy Young, MD. Director, Hemostasis and Read the full article...

Date: Wednesday, November 29, 2023 Time: 1:00pm - 2:00pm ET TITLE: Overview of Adzynma (rADAMTS13) Prescribing Information OBJECTIVE: Inform on the new approval and prescribing information of Adzynma indicated for prophylactic and on-demand use for patients with congenital TTP. TARGET AUDIENCE: Hematologists, NPs, nurses, pharmacists SPEAKER: Ali Mokdad, MD, PhD, MBA, Medical Director, Takeda

Date: Tuesday, January 23, 2024 Time: 1:00pm - 2:00pm ET TITLE: Real-world Characterization of Female Hemophilia A Carriers in the US OBJECTIVE: Summarize recently published real-world data on Female Hemophilia A Carriers in the US, including clinical and healthcare resource utilization information. TARGET AUDIENCE: Hematologists, NPs, nurses, pharmacists SPEAKER: Jorge Caicedo, MD, Sr. Medical Director, Read the full article...

Date: Tuesday, March 5, 2024 Time: 1:00pm - 2:00pm ET TITLE: Advocating for Access to Behavioral Health Treatment for the Bleeding Disorders Community WEBINAR OBJECTIVE: This presentation will educate HTC providers about the barriers to access to inpatient and residential mental health and substance use treatment facilities for people with bleeding disorders. It will provide Read the full article...

Date: Thursday, March 14, 2024 Time: 1:00pm - 2:00pm ET TITLE: Exploring the Science and Possibilities of Gene Therapy in Hemophilia WEBINAR OVERVIEW: By attending this webinar, you will discover the scientific approach of gene therapy, understand gene therapy objectives for patients with hemophilia, and explore the shared decision-making process to accompany your patients in Read the full article...

Date: Tuesday, May 7, 2024 Time: 2:00pm - 3:00pm ET TITLE: Reinforcing 10+ years of clinical trial experience with a subcutaneous prophylaxis treatment, including the latest data in infants WEBINAR OBJECTIVE: Dr. Mike Silvey will share his perspective on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal Read the full article...

Date: Tuesday, May 14, 2024 Time: 2:00pm - 3:00pm ET TITLE: Hemophilia Alliance Network Services/Emerging Therapy Solutions A Gene Therapy Payer Contract WEBINAR DESCRIPTION: The past twelve to eighteen months have been landmark times for gene therapy treatments for individuals with bleeding disorders. While the third party payers, reinsurers and prescription benefit plans have begun Read the full article...